Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors

Next Previous
Trial Profile

Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEO201 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms QUILT-3.017
  • Sponsors Precision Biologics

Most Recent Events

  • 24 Apr 2025 Planned End Date changed from 15 Oct 2026 to 15 Jan 2029.
  • 24 Apr 2025 Planned primary completion date changed from 15 Oct 2025 to 15 Jan 2028.
  • 04 Jun 2024 Results assessing Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top